Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 15.51 EUR 0.06% Market Closed
Market Cap: 512.9m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MEDCL stock under the Base Case scenario is 6.1 EUR. Compared to the current market price of 15.51 EUR, Medincell SA is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEDCL Relative Value
Base Case
6.1 EUR
Overvaluation 61%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

48.1
P/S
P/S
Price to Sales
48.1
vs History
33
vs Industry
5
Median 3Y
41.2
Median 5Y
43.6
Industry
2.4
Forward
15.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-12
Industry
20.5
Forward
-21.6
More Details
24
P/OCF
P/OCF
Price to OCF
24
vs History
4
vs Industry
19
Median 3Y
-9.9
Median 5Y
-14
Industry
15.6
More Details
48.2
P/FCFE
P/FCFE
Price to FCFE
48.2
vs History
4
vs Industry
12
Median 3Y
-10.2
Median 5Y
-15.1
Industry
23.1
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-11.1
Industry
2
More Details
49.3
EV/S
EV/S
Enterprise Value to Sales
49.3
vs History
33
vs Industry
5
Median 3Y
39.3
Median 5Y
42.2
Industry
2.5
Forward
15.9
More Details
53.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
53.8
vs History
42
vs Industry
4
Median 3Y
51.5
Median 5Y
51.9
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-13.5
Median 5Y
-16.5
Industry
12.3
Forward
-58.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.5
Median 5Y
-15.2
Industry
15.5
Forward
-51.2
More Details
24.6
EV/OCF
EV/OCF
Enterprise Value to OCF
24.6
vs History
4
vs Industry
18
Median 3Y
-10.4
Median 5Y
-14.4
Industry
14.1
More Details
26.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
26.2
vs History
4
vs Industry
19
Median 3Y
-10
Median 5Y
-13.7
Industry
17.5
More Details
29.8
EV/IC
EV/IC
Enterprise Value to IC
29.8
vs History
26
vs Industry
4
Median 3Y
16.1
Median 5Y
22
Industry
1.8
More Details

Multiples Across Competitors

MEDCL Competitors Multiples
Medincell SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Medincell SA
PAR:MEDCL
512.9m EUR 48.1 -16.3 -29.5 -26.9
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
FR
Medincell SA
PAR:MEDCL
Average P/E: 23.5
Negative Multiple: -16.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBITDA: 433
Negative Multiple: -29.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Medincell SA
PAR:MEDCL
Average EV/EBIT: 1 866.2
Negative Multiple: -26.9 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
MEDCL intrinsic value, competitors valuation, and company profile.
DCF Valuation
MEDCL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MEDCL stock valuation using valuation multiples.
Wall Street Estimates
MEDCL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MEDCL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.